

# Non-Small Cell Lung Cancer - Pipeline Review, H2 2017

<https://marketpublishers.com/r/NA28E2E58C0EN.html>

Date: December 2017

Pages: 2678

Price: US\$ 2,500.00 (Single User License)

ID: NA28E2E58C0EN

## Abstracts

Non-Small Cell Lung Cancer - Pipeline Review, H2 2017

### SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Non-Small Cell Lung Cancer - Pipeline Review, H2 2017, provides an overview of the Non-Small Cell Lung Cancer (Oncology) pipeline landscape.

Non-small cell lung cancer (NSCLC) is the most common type of lung cancer. NSCLC is a cancer (malignancy) that originates in the tissues of the lungs or the cells lining the airways. Symptoms of lung cancer usually occur in later stages of the disease. The signs and symptoms include persistent cough that may get worse over time, trouble breathing or shortness of breath, constant chest pain or discomfort, bloody phlegm or spit (sputum), fatigue and weakness and unintentional weight loss. The disease might be controlled with the help of medications, chemotherapy and modifications in lifestyle.

### REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Non-Small Cell Lung Cancer - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Non-Small Cell Lung Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Non-Small Cell Lung Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Non-Small Cell Lung Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 9, 47, 206, 192, 18, 167, 19 and 15 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 13, 14, 45 and 5 molecules, respectively.

Non-Small Cell Lung Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

**Note:** Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Non-Small Cell Lung Cancer (Oncology).

The pipeline guide reviews pipeline therapeutics for Non-Small Cell Lung Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Non-Small Cell Lung

Cancer (Oncology) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Non-Small Cell Lung Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Non-Small Cell Lung Cancer (Oncology)

## **REASONS TO BUY**

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Non-Small Cell Lung Cancer (Oncology).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Non-Small Cell Lung Cancer (Oncology) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

## Contents

Introduction

Non-Small Cell Lung Cancer - Overview

Non-Small Cell Lung Cancer - Therapeutics Development

Non-Small Cell Lung Cancer - Therapeutics Assessment

Non-Small Cell Lung Cancer - Companies Involved in Therapeutics Development

Non-Small Cell Lung Cancer - Drug Profiles

Non-Small Cell Lung Cancer - Dormant Projects 2564

Non-Small Cell Lung Cancer - Discontinued Products 2586

Non-Small Cell Lung Cancer - Product Development Milestones 2595

Appendix 2606

## List Of Tables

### LIST OF TABLES

Number of Products under Development for Non-Small Cell Lung Cancer, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Companies, H2 2017 (Contd.1), H2 2017

Number of Products under Development by Companies, H2 2017 (Contd.2), H2 2017

Number of Products under Development by Companies, H2 2017 (Contd.3), H2 2017

Number of Products under Development by Companies, H2 2017 (Contd.4), H2 2017

Number of Products under Development by Companies, H2 2017 (Contd.5), H2 2017

Number of Products under Development by Companies, H2 2017 (Contd.6), H2 2017

Number of Products under Development by Companies, H2 2017 (Contd.7), H2 2017

Number of Products under Development by Companies, H2 2017 (Contd.8), H2 2017

Number of Products under Development by Companies, H2 2017 (Contd.9), H2 2017

Number of Products under Development by Companies, H2 2017 (Contd.10), H2 2017

Number of Products under Development by Companies, H2 2017 (Contd.11), H2 2017

Number of Products under Development by Companies, H2 2017 (Contd.12), H2 2017

Number of Products under Development by Companies, H2 2017 (Contd.13), H2 2017

Number of Products under Development by Companies, H2 2017 (Contd.14), H2 2017

Number of Products under Development by Companies, H2 2017 (Contd.15), H2 2017

Number of Products under Development by Companies, H2 2017 (Contd.16), H2 2017

Number of Products under Development by Companies, H2 2017 (Contd.17), H2 2017

Number of Products under Development by Companies, H2 2017 (Contd.18), H2 2017

Number of Products under Development by Companies, H2 2017 (Contd.19), H2 2017

Number of Products under Development by Companies, H2 2017 (Contd.20), H2 2017

Number of Products under Development by Companies, H2 2017 (Contd.21), H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Number of Products under Development by Universities/Institutes, H2 2017 (Contd.1), H2 2017

Number of Products under Development by Universities/Institutes, H2 2017 (Contd.2), H2 2017

Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017 (Contd.1), H2 2017

Products under Development by Companies, H2 2017 (Contd.2), H2 2017

Products under Development by Companies, H2 2017 (Contd.3), H2 2017

Products under Development by Companies, H2 2017 (Contd.4), H2 2017

Products under Development by Companies, H2 2017 (Contd.5), H2 2017

Products under Development by Companies, H2 2017 (Contd.6), H2 2017

Products under Development by Companies, H2 2017 (Contd.7), H2 2017  
Products under Development by Companies, H2 2017 (Contd.8), H2 2017  
Products under Development by Companies, H2 2017 (Contd.9), H2 2017  
Products under Development by Companies, H2 2017 (Contd.10), H2 2017  
Products under Development by Companies, H2 2017 (Contd.11), H2 2017  
Products under Development by Companies, H2 2017 (Contd.12), H2 2017  
Products under Development by Companies, H2 2017 (Contd.13), H2 2017  
Products under Development by Companies, H2 2017 (Contd.14), H2 2017  
Products under Development by Companies, H2 2017 (Contd.15), H2 2017  
Products under Development by Companies, H2 2017 (Contd.16), H2 2017  
Products under Development by Companies, H2 2017 (Contd.17), H2 2017  
Products under Development by Companies, H2 2017 (Contd.18), H2 2017  
Products under Development by Companies, H2 2017 (Contd.19), H2 2017  
Products under Development by Companies, H2 2017 (Contd.20), H2 2017  
Products under Development by Companies, H2 2017 (Contd.21), H2 2017  
Products under Development by Companies, H2 2017 (Contd.22), H2 2017  
Products under Development by Companies, H2 2017 (Contd.23), H2 2017  
Products under Development by Companies, H2 2017 (Contd.24), H2 2017  
Products under Development by Companies, H2 2017 (Contd.25), H2 2017  
Products under Development by Companies, H2 2017 (Contd.26), H2 2017  
Products under Development by Companies, H2 2017 (Contd.27), H2 2017  
Products under Development by Companies, H2 2017 (Contd.28), H2 2017  
Products under Development by Companies, H2 2017 (Contd.29), H2 2017  
Products under Development by Companies, H2 2017 (Contd.30), H2 2017  
Products under Development by Companies, H2 2017 (Contd.31), H2 2017  
Products under Development by Companies, H2 2017 (Contd.32), H2 2017  
Products under Development by Companies, H2 2017 (Contd.33), H2 2017  
Products under Development by Companies, H2 2017 (Contd.34), H2 2017  
Products under Development by Companies, H2 2017 (Contd.35), H2 2017  
Products under Development by Companies, H2 2017 (Contd.36), H2 2017  
Products under Development by Companies, H2 2017 (Contd.37), H2 2017  
Products under Development by Companies, H2 2017 (Contd.38), H2 2017  
Products under Development by Companies, H2 2017 (Contd.39), H2 2017  
Products under Development by Companies, H2 2017 (Contd.40), H2 2017  
Products under Development by Universities/Institutes, H2 2017  
Products under Development by Universities/Institutes, H2 2017 (Contd.1), H2 2017  
Products under Development by Universities/Institutes, H2 2017 (Contd.2), H2 2017  
Products under Development by Universities/Institutes, H2 2017 (Contd.3), H2 2017  
Number of Products by Stage and Target, H2 2017



Number of Products by Stage and Target, H2 2017 (Contd.1), H2 2017  
Number of Products by Stage and Target, H2 2017 (Contd.2), H2 2017  
Number of Products by Stage and Target, H2 2017 (Contd.3), H2 2017  
Number of Products by Stage and Target, H2 2017 (Contd.4), H2 2017  
Number of Products by Stage and Target, H2 2017 (Contd.5), H2 2017  
Number of Products by Stage and Target, H2 2017 (Contd.6), H2 2017  
Number of Products by Stage and Target, H2 2017 (Contd.7), H2 2017  
Number of Products by Stage and Target, H2 2017 (Contd.8), H2 2017  
Number of Products by Stage and Target, H2 2017 (Contd.9), H2 2017  
Number of Products by Stage and Target, H2 2017 (Contd.10), H2 2017  
Number of Products by Stage and Target, H2 2017 (Contd.11), H2 2017  
Number of Products by Stage and Target, H2 2017 (Contd.12), H2 2017  
Number of Products by Stage and Target, H2 2017 (Contd.13), H2 2017  
Number of Products by Stage and Target, H2 2017 (Contd.14), H2 2017  
Number of Products by Stage and Mechanism of Action, H2 2017  
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd.1), H2 2017  
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd.2), H2 2017  
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd.3), H2 2017  
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd.4), H2 2017  
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd.5), H2 2017  
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd.6), H2 2017  
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd.7), H2 2017  
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd.8), H2 2017  
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd.9), H2 2017  
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd.10), H2 2017  
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd.11), H2 2017  
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd.12), H2 2017  
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd.13), H2 2017  
Number of Products by Stage and Route of Administration, H2 2017  
Number of Products by Stage and Molecule Type, H2 2017  
Non-Small Cell Lung Cancer - Pipeline by 3-V Biosciences Inc, H2 2017  
Non-Small Cell Lung Cancer - Pipeline by 3SBio Inc, H2 2017  
Non-Small Cell Lung Cancer - Pipeline by 4SC AG, H2 2017  
Non-Small Cell Lung Cancer - Pipeline by AbbVie Inc, H2 2017  
Non-Small Cell Lung Cancer - Pipeline by Ability Pharmaceuticals SL, H2 2017  
Non-Small Cell Lung Cancer - Pipeline by ACEA Biosciences Inc, H2 2017  
Non-Small Cell Lung Cancer - Pipeline by Adamed Sp z oo, H2 2017  
Non-Small Cell Lung Cancer - Pipeline by Adaptimmune Therapeutics Plc, H2 2017  
Non-Small Cell Lung Cancer - Pipeline by ADC Therapeutics Sarl, H2 2017



Non-Small Cell Lung Cancer - Pipeline by Aduro BioTech Inc, H2 2017

Non-Small Cell Lung Cancer - Pipeline by Advantagene Inc, H2 2017

Non-Small Cell Lung Cancer - Pipeline by Advaxis Inc, H2 2017

Non-Small Cell Lung Cancer - Pipeline by Advenchen Laboratories LLC, H2 2017

Non-Small Cell Lung Cancer - Pipeline by Agenus Inc, H2 2017

Non-Small Cell Lung Cancer - Pipeline by Allist Shanghai Pharmaceutical Technology Co Ltd, H2 2017

Non-Small Cell Lung Cancer - Pipeline by Altimmune Inc, H2 2017

Non-Small Cell Lung Cancer - Pipeline by Altor BioScience Corp, H2 2017

Non-Small Cell Lung Cancer - Pipeline by Amgen Inc, H2 2017

Non-Small Cell Lung Cancer - Pipeline by Andarix Pharmaceuticals Inc, H2 2017

Non-Small Cell Lung Cancer - Pipeline by AndroScience Corp, H2 2017

Non-Small Cell Lung Cancer - Pipeline by Apexigen Inc, H2 2017

Non-Small Cell Lung Cancer - Pipeline by Aptose Biosciences Inc, H2 2017

Non-Small Cell Lung Cancer - Pipeline by Argos Therapeutics Inc, H2 2017

Non-Small Cell Lung Cancer - Pipeline by Ariad Pharmaceuticals Inc, H2 2017

Non-Small Cell Lung Cancer - Pipeline by ARMO Biosciences Inc, H2 2017

Non-Small Cell Lung Cancer - Pipeline by ArQule Inc, H2 2017

Non-Small Cell Lung Cancer - Pipeline by Array BioPharma Inc, H2 2017

Non-Small Cell Lung Cancer - Pipeline by Asana BioSciences LLC, H2 2017

Non-Small Cell Lung Cancer - Pipeline by Ascentage Pharma Group Corp Ltd, H2 2017

Non-Small Cell Lung Cancer - Pipeline by Astellas Pharma Inc, H2 2017

Non-Small Cell Lung Cancer - Pipeline by Asterias Biotherapeutics Inc, H2 2017

Non-Small Cell Lung Cancer - Pipeline by Astex Pharmaceuticals Inc, H2 2017

Non-Small Cell Lung Cancer - Pipeline by AstraZeneca Plc, H2 2017

Non-Small Cell Lung Cancer - Pipeline by Atreca Inc, H2 2017

Non-Small Cell Lung Cancer - Pipeline by Aurigene Discovery Technologies Ltd, H2 2017

Non-Small Cell Lung Cancer - Pipeline by Aurobindo Pharma Ltd, H2 2017

Non-Small Cell Lung Cancer - Pipeline by AVEO Pharmaceuticals Inc, H2 2017

Non-Small Cell Lung Cancer - Pipeline by Basilea Pharmaceutica Ltd, H2 2017

Non-Small Cell Lung Cancer - Pipeline by Batu Biologics Inc, H2 2017

Non-Small Cell Lung Cancer - Pipeline by Bavarian Nordic A/S, H2 2017

Non-Small Cell Lung Cancer - Pipeline by Bayer AG, H2 2017

Non-Small Cell Lung Cancer - Pipeline by BeiGene Ltd, H2 2017

Non-Small Cell Lung Cancer - Pipeline by Beijing Hanmi Pharmaceutical Co Ltd, H2 2017

Non-Small Cell Lung Cancer - Pipeline by BerGenBio ASA, H2 2017

Non-Small Cell Lung Cancer - Pipeline by Beta Pharma Inc, H2 2017

Non-Small Cell Lung Cancer - Pipeline by Betta Pharmaceuticals Co Ltd, H2 2017  
Non-Small Cell Lung Cancer - Pipeline by BeyondSpring Pharmaceuticals Inc, H2 2017  
Non-Small Cell Lung Cancer - Pipeline by Bicycle Therapeutics Ltd, H2 2017  
Non-Small Cell Lung Cancer - Pipeline by Bio-Cancer Treatment International Ltd, H2 2017  
Non-Small Cell Lung Cancer - Pipeline by Biocad, H2 2017  
Non-Small Cell Lung Cancer - Pipeline by BioCancell Ltd, H2 2017  
Non-Small Cell Lung Cancer - Pipeline by Biocon Ltd, H2 2017  
Non-Small Cell Lung Cancer - Pipeline by Biohaven Pharmaceutical Holding Company Ltd, H2 2017  
Non-Small Cell Lung Cancer - Pipeline by BioLineRx Ltd, H2 2017  
Non-Small Cell Lung Cancer - Pipeline by Bionovis SA, H2 2017  
Non-Small Cell Lung Cancer - Pipeline by Biothera Pharmaceutical Inc, H2 2017  
Non-Small Cell Lung Cancer - Pipeline by Blueprint Medicines Corp, H2 2017  
Non-Small Cell Lung Cancer - Pipeline by Boehringer Ingelheim GmbH, H2 2017  
Non-Small Cell Lung Cancer - Pipeline by Boston Biomedical Inc, H2 2017  
Non-Small Cell Lung Cancer - Pipeline by BrightPath Biotherapeutics Co Ltd, H2 2017  
Non-Small Cell Lung Cancer - Pipeline by Bristol-Myers Squibb Co, H2 2017  
Non-Small Cell Lung Cancer - Pipeline by Cadila Healthcare Ltd, H2 2017  
Non-Small Cell Lung Cancer - Pipeline by Calithera Biosciences Inc, H2 2017  
Non-Small Cell Lung Cancer - Pipeline by CanBas Co Ltd, H2 2017  
Non-Small Cell Lung Cancer - Pipeline by Cantargia AB, H2 2017  
Non-Small Cell Lung Cancer - Pipeline by Cascadian Therapeutics Inc, H2 2017  
Non-Small Cell Lung Cancer - Pipeline by CASI Pharmaceuticals Inc, H2 2017  
Non-Small Cell Lung Cancer - Pipeline by CBT Pharmaceuticals Inc, H2 2017  
Non-Small Cell Lung Cancer - Pipeline by Celgene Corp, H2 2017  
Non-Small Cell Lung Cancer - Pipeline by Cell Medica Ltd, H2 2017  
Non-Small Cell Lung Cancer - Pipeline by Celldex Therapeutics Inc, H2 2017  
Non-Small Cell Lung Cancer - Pipeline by Cellmid Ltd, H2 2017  
Non-Small Cell Lung Cancer - Pipeline by Cellular Biomedicine Group Inc, H2 2017  
Non-Small Cell Lung Cancer - Pipeline by Checkpoint Therapeutics Inc, H2 2017  
Non-Small Cell Lung Cancer - Pipeline by Chipscreen Biosciences Ltd, H2 2017  
Non-Small Cell Lung Cancer - Pipeline by Chugai Pharmaceutical Co Ltd, H2 2017  
Non-Small Cell Lung Cancer - Pipeline by Cielo Therapeutics Inc, H2 2017  
Non-Small Cell Lung Cancer - Pipeline by Cleave Biosciences Inc, H2 2017  
Non-Small Cell Lung Cancer - Pipeline by Cleveland BioLabs Inc, H2 2017  
Non-Small Cell Lung Cancer - Pipeline by Coherus BioSciences Inc, H2 2017  
Non-Small Cell Lung Cancer - Pipeline by Corcept Therapeutics Inc, H2 2017  
Non-Small Cell Lung Cancer - Pipeline by Cortice Biosciences Inc, H2 2017

Non-Small Cell Lung Cancer - Pipeline by Corvus Pharmaceuticals Inc, H2 2017  
Non-Small Cell Lung Cancer - Pipeline by Critical Outcome Technologies Inc, H2 2017  
Non-Small Cell Lung Cancer - Pipeline by CSPC Pharmaceutical Group Limited, H2 2017  
Non-Small Cell Lung Cancer - Pipeline by CytomX Therapeutics Inc, H2 2017  
Non-Small Cell Lung Cancer - Pipeline by Cytori Therapeutics Inc, H2 2017  
Non-Small Cell Lung Cancer - Pipeline by DAE HWA Pharmaceutical Co Ltd, H2 2017  
Non-Small Cell Lung Cancer - Pipeline by Daiichi Sankyo Co Ltd, H2 2017  
Non-Small Cell Lung Cancer - Pipeline by DanDrit Biotech A/S, H2 2017  
Non-Small Cell Lung Cancer - Pipeline by Debiopharm International SA, H2 2017  
Non-Small Cell Lung Cancer - Pipeline by DEKK-TEC Inc, H2 2017  
Non-Small Cell Lung Cancer - Pipeline by DelMar Pharmaceuticals Inc, H2 2017  
Non-Small Cell Lung Cancer - Pipeline by Denovo Biopharma LLC, H2 2017  
Non-Small Cell Lung Cancer - Pipeline by Domainex Ltd, H2 2017  
Non-Small Cell Lung Cancer - Pipeline by Double Bond Pharmaceutical International AB, H2 2017  
Non-Small Cell Lung Cancer - Pipeline by Dr. Reddy's Laboratories Ltd, H2 2017  
Non-Small Cell Lung Cancer - Pipeline by Dynavax Technologies Corp, H2 2017  
Non-Small Cell Lung Cancer - Pipeline by eFFECTOR Therapeutics Inc, H2 2017  
Non-Small Cell Lung Cancer - Pipeline by Eisai Co Ltd, H2 2017  
Non-Small Cell Lung Cancer - Pipeline by Eleison Pharmaceuticals LLC, H2 2017  
Non-Small Cell Lung Cancer - Pipeline by Eli Lilly and Co, H2 2017  
Non-Small Cell Lung Cancer - Pipeline by EnGeneIC Ltd, H2 2017  
Non-Small Cell Lung Cancer - Pipeline by EntreChem SL, H2 2017  
Non-Small Cell Lung Cancer - Pipeline by Enumeral Biomedical Holdings Inc, H2 2017  
Non-Small Cell Lung Cancer - Pipeline by Enzene Biosciences Ltd, H2 2017  
Non-Small Cell Lung Cancer - Pipeline by EpiThany Inc, H2 2017  
Non-Small Cell Lung Cancer - Pipeline by Epizyme Inc, H2 2017  
Non-Small Cell Lung Cancer - Pipeline by Eudendron Srl, H2 2017  
Non-Small Cell Lung Cancer - Pipeline by Evotec AG, H2 2017  
Non-Small Cell Lung Cancer - Pipeline by Exelixis Inc, H2 2017  
Non-Small Cell Lung Cancer - Pipeline by F-star Biotechnology Ltd, H2 2017  
Non-Small Cell Lung Cancer - Pipeline by F. Hoffmann-La Roche Ltd, H2 2017  
Non-Small Cell Lung Cancer - Pipeline by FibroStatin SL, H2 2017  
Non-Small Cell Lung Cancer - Pipeline by Five Prime Therapeutics Inc, H2 2017  
Non-Small Cell Lung Cancer - Pipeline by Formosa Laboratories Inc, H2 2017  
Non-Small Cell Lung Cancer - Pipeline by Fountain Biopharma Inc, H2 2017  
Non-Small Cell Lung Cancer - Pipeline by Fujifilm Holdings Corporation, H2 2017  
Non-Small Cell Lung Cancer - Pipeline by G&E Herbal Biotechnology Co Ltd, H2 2017

Non-Small Cell Lung Cancer - Pipeline by G1 Therapeutics Inc, H2 2017  
Non-Small Cell Lung Cancer - Pipeline by Galectin Therapeutics Inc, H2 2017  
Non-Small Cell Lung Cancer - Pipeline by Gene Techno Science Co Ltd, H2 2017  
Non-Small Cell Lung Cancer - Pipeline by Genelux Corp, H2 2017  
Non-Small Cell Lung Cancer - Pipeline by Genentech Inc, H2 2017  
Non-Small Cell Lung Cancer - Pipeline by Genmab A/S, H2 2017  
Non-Small Cell Lung Cancer - Pipeline by Genocea Biosciences Inc, H2 2017  
Non-Small Cell Lung Cancer - Pipeline by Genor BioPharma Co Ltd, H2 2017  
Non-Small Cell Lung Cancer - Pipeline by Genosco Inc, H2 2017  
Non-Small Cell Lung Cancer - Pipeline by Genzyme Corp, H2 2017  
Non-Small Cell Lung Cancer - Pipeline by Gilead Sciences Inc, H2 2017  
Non-Small Cell Lung Cancer - Pipeline by GlaxoSmithKline Plc, H2 2017  
Non-Small Cell Lung Cancer - Pipeline by Glenmark Pharmaceuticals Ltd, H2 2017  
Non-Small Cell Lung Cancer - Pipeline by GlycaNova Norway AS, H2 2017  
Non-Small Cell Lung Cancer - Pipeline by Glycotope GmbH, H2 2017  
Non-Small Cell Lung Cancer - Pipeline by Golden Biotechnology Corp, H2 2017  
Non-Small Cell Lung Cancer - Pipeline by Gradalis Inc, H2 2017  
Non-Small Cell Lung Cancer - Pipeline by Grunenthal GmbH, H2 2017  
Non-Small Cell Lung Cancer - Pipeline by Halozyme Therapeutics Inc, H2 2017  
Non-Small Cell Lung Cancer - Pipeline by Hanmi Pharmaceuticals Co Ltd, H2 2017  
Non-Small Cell Lung Cancer - Pipeline by Heat Biologics Inc, H2 2017  
Non-Small Cell Lung Cancer - Pipeline by Helix BioPharma Corp, H2 2017  
Non-Small Cell Lung Cancer - Pipeline by Hemispherx Biopharma Inc, H2 2017  
Non-Small Cell Lung Cancer - Pipeline by Heptares Therapeutics Ltd, H2 2017  
Non-Small Cell Lung Cancer - Pipeline by HitGen LTD, H2 2017  
Non-Small Cell Lung Cancer - Pipeline by Horizon Pharma Plc, H2 2017  
Non-Small Cell Lung Cancer - Pipeline by Hutchison MediPharma Ltd, H2 2017  
Non-Small Cell Lung Cancer - Pipeline by iCeutica Inc, H2 2017  
Non-Small Cell Lung Cancer - Pipeline by Ideaya Biosciences Inc, H2 2017  
Non-Small Cell Lung Cancer - Pipeline by Ignyta Inc, H2 2017  
Non-Small Cell Lung Cancer - Pipeline by Immatics Biotechnologies GmbH, H2 2017  
Non-Small Cell Lung Cancer - Pipeline by Immune Design Corp, H2 2017  
Non-Small Cell Lung Cancer - Pipeline by Immune Pharmaceuticals Inc, H2 2017  
Non-Small Cell Lung Cancer - Pipeline by ImmunGene Inc, H2 2017  
Non-Small Cell Lung Cancer - Pipeline by Immunocore Ltd, H2 2017  
Non-Small Cell Lung Cancer - Pipeline by ImmunoGen Inc, H2 2017  
Non-Small Cell Lung Cancer - Pipeline by Immunomedics Inc, H2 2017  
Non-Small Cell Lung Cancer - Pipeline by Imugene Ltd, H2 2017  
Non-Small Cell Lung Cancer - Pipeline by Incyte Corp, H2 2017

Non-Small Cell Lung Cancer - Pipeline by Infinity Pharmaceuticals Inc, H2 2017  
Non-Small Cell Lung Cancer - Pipeline by Inflection Biosciences Ltd, H2 2017  
Non-Small Cell Lung Cancer - Pipeline by Innovation Pharmaceuticals Inc, H2 2017  
Non-Small Cell Lung Cancer - Pipeline by Innovent Biologics Inc, H2 2017  
Non-Small Cell Lung Cancer - Pipeline by Inovio Pharmaceuticals Inc, H2 2017  
Non-Small Cell Lung Cancer - Pipeline by Invectys SA, H2 2017  
Non-Small Cell Lung Cancer - Pipeline by Inventiva, H2 2017  
Non-Small Cell Lung Cancer - Pipeline by IO Biotech ApS, H2 2017  
Non-Small Cell Lung Cancer - Pipeline by Io Therapeutics Inc, H2 2017  
Non-Small Cell Lung Cancer - Pipeline by Iovance Biotherapeutics Inc, H2 2017  
Non-Small Cell Lung Cancer - Pipeline by JHL Biotech Inc, H2 2017  
Non-Small Cell Lung Cancer - Pipeline by Jiangsu Hansoh Pharmaceutical Group Co Ltd, H2 2017  
Non-Small Cell Lung Cancer - Pipeline by Jiangsu Hengrui Medicine Co Ltd, H2 2017  
Non-Small Cell Lung Cancer - Pipeline by Jiangsu Kanion Pharmaceutical Co Ltd, H2 2017  
Non-Small Cell Lung Cancer - Pipeline by Johnson & Johnson, H2 2017  
Non-Small Cell Lung Cancer - Pipeline by Jounce Therapeutics Inc, H2 2017  
Non-Small Cell Lung Cancer - Pipeline by Juno Therapeutics Inc, H2 2017  
Non-Small Cell Lung Cancer - Pipeline by Kadmon Corp LLC, H2 2017  
Non-Small Cell Lung Cancer - Pipeline by Karyopharm Therapeutics Inc, H2 2017  
Non-Small Cell Lung Cancer - Pipeline by Kite Pharma Inc, H2 2017  
Non-Small Cell Lung Cancer - Pipeline by Kura Oncology Inc, H2 2017  
Non-Small Cell Lung Cancer - Pipeline by Kyowa Hakko Kirin Co Ltd, H2 2017  
Non-Small Cell Lung Cancer - Pipeline by Laboratoires Pierre Fabre SA, H2 2017  
Non-Small Cell Lung Cancer - Pipeline by LATITUDE Pharmaceuticals Inc, H2 2017  
Non-Small Cell Lung Cancer - Pipeline by Leap Therapeutics Inc, H2 2017  
Non-Small Cell Lung Cancer - Pipeline by Les Laboratoires Servier SAS, H2 2017  
Non-Small Cell Lung Cancer - Pipeline by Lidds AB, H2 2017  
Non-Small Cell Lung Cancer - Pipeline by Loxo Oncology Inc, H2 2017  
Non-Small Cell Lung Cancer - Pipeline by Luye Pharma Group Ltd, H2 2017  
Non-Small Cell Lung Cancer - Pipeline by Lycera Corp, H2 2017  
Non-Small Cell Lung Cancer - Pipeline by MabVax Therapeutics Holdings Inc, H2 2017  
Non-Small Cell Lung Cancer - Pipeline by MacroGenics Inc, H2 2017  
Non-Small Cell Lung Cancer - Pipeline by Madrigal Pharmaceuticals Inc., H2 2017  
Non-Small Cell Lung Cancer - Pipeline by Mallinckrodt Plc, H2 2017  
Non-Small Cell Lung Cancer - Pipeline by Mebiopharm Co Ltd, H2 2017  
Non-Small Cell Lung Cancer - Pipeline by MedImmune LLC, H2 2017  
Non-Small Cell Lung Cancer - Pipeline by Merck & Co Inc, H2 2017



Non-Small Cell Lung Cancer - Pipeline by Merck KGaA, H2 2017  
Non-Small Cell Lung Cancer - Pipeline by Merrimack Pharmaceuticals Inc, H2 2017  
Non-Small Cell Lung Cancer - Pipeline by Mersana Therapeutics Inc, H2 2017  
Non-Small Cell Lung Cancer - Pipeline by Merus NV, H2 2017  
Non-Small Cell Lung Cancer - Pipeline by Microlin Bio Inc, H2 2017  
Non-Small Cell Lung Cancer - Pipeline by Millennium Pharmaceuticals Inc, H2 2017  
Non-Small Cell Lung Cancer - Pipeline by Mirati Therapeutics Inc, H2 2017  
Non-Small Cell Lung Cancer - Pipeline by Moderna Therapeutics Inc, H2 2017  
Non-Small Cell Lung Cancer - Pipeline by Molecular Partners AG, H2 2017  
Non-Small Cell Lung Cancer - Pipeline by MolMed SpA, H2 2017  
Non-Small Cell Lung Cancer - Pipeline by Morphotek Inc, H2 2017  
Non-Small Cell Lung Cancer - Pipeline by Multimmune GmbH, H2 2017  
Non-Small Cell Lung Cancer - Pipeline by Mundipharma International Ltd, H2 2017  
Non-Small Cell Lung Cancer - Pipeline by Mycenax Biotech Inc, H2 2017  
Non-Small Cell Lung Cancer - Pipeline by NanoCarrier Co Ltd, H2 2017  
Non-Small Cell Lung Cancer - Pipeline by NantKwest Inc, H2 2017  
Non-Small Cell Lung Cancer - Pipeline by Natco Pharma Ltd, H2 2017  
Non-Small Cell Lung Cancer - Pipeline by Nektar Therapeutics, H2 2017  
Non-Small Cell Lung Cancer - Pipeline by Neumedicines Inc, H2 2017  
Non-Small Cell Lung Cancer - Pipeline by NewLink Genetics Corp, H2 2017  
Non-Small Cell Lung Cancer - Pipeline by Northwest Biotherapeutics Inc, H2 2017  
Non-Small Cell Lung Cancer - Pipeline by Novartis AG, H2 2017  
Non-Small Cell Lung Cancer - Pipeline by Oncobiologics Inc, H2 2017  
Non-Small Cell Lung Cancer - Pipeline by Oncolys BioPharma Inc, H2 2017  
Non-Small Cell Lung Cancer - Pipeline by Oncolytics Biotech Inc, H2 2017  
Non-Small Cell Lung Cancer - Pipeline by Ono Pharmaceutical Co Ltd, H2 2017  
Non-Small Cell Lung Cancer - Pipeline by Onxeo SA, H2 2017  
Non-Small Cell Lung Cancer - Pipeline by Optimum Therapeutics LLC, H2 2017

## List Of Figures

### LIST OF FIGURES

|  |     |
|--|-----|
| Number of Products under Development for Non-Small Cell Lung Cancer, H2 2017 | 86  |
| Number of Products under Development by Companies, H2 2017                   | 87  |
| Number of Products under Development by Universities/Institutes, H2 2017     | 110 |
| Number of Products by Top 10 Targets, H2 2017                                | 159 |
| Number of Products by Stage and Top 10 Targets, H2 2017                      | 159 |
| Number of Products by Top 10 Mechanism of Actions, H2 2017                   | 175 |
| Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017         | 175 |
| Number of Products by Top 10 Routes of Administration, H2 2017               | 190 |
| Number of Products by Stage and Top 10 Routes of Administration, H2 2017     | 190 |
| Number of Products by Top 10 Molecule Types, H2 2017                         | 192 |
| Number of Products by Stage and Top 10 Molecule Types, H2 2017               | 192 |

### COMPANIES MENTIONED

3-V Biosciences Inc  
3SBio Inc  
4SC AG  
AbbVie Inc  
Ability Pharmaceuticals SL  
ACEA Biosciences Inc  
Adamed Sp z oo  
Adaptimmune Therapeutics Plc  
ADC Therapeutics Sarl  
Aduro BioTech Inc  
Advantagene Inc  
Advaxis Inc  
Advenchen Laboratories LLC  
Agenus Inc  
Allist Shanghai Pharmaceutical Technology Co Ltd  
Altimune Inc  
Altor BioScience Corp  
Amgen Inc  
Andarix Pharmaceuticals Inc  
AndroScience Corp  
Apexigen Inc



Aptose Biosciences Inc  
Argos Therapeutics Inc  
Ariad Pharmaceuticals Inc  
ARMO Biosciences Inc  
ArQule Inc  
Array BioPharma Inc  
Asana BioSciences LLC  
Ascentage Pharma Group Corp Ltd  
Astellas Pharma Inc  
Asterias Biotherapeutics Inc  
Astex Pharmaceuticals Inc  
AstraZeneca Plc  
Atreca Inc  
Aurigene Discovery Technologies Ltd  
Aurobindo Pharma Ltd  
AVEO Pharmaceuticals Inc  
Basilea Pharmaceutica Ltd  
Batu Biologics Inc  
Bavarian Nordic A/S  
Bayer AG  
BeiGene Ltd  
Beijing Hanmi Pharmaceutical Co Ltd  
BerGenBio ASA  
Beta Pharma Inc  
Betta Pharmaceuticals Co Ltd  
BeyondSpring Pharmaceuticals Inc  
Bicycle Therapeutics Ltd  
Bio-Cancer Treatment International Ltd  
Biocad  
BioCancell Ltd  
Biocon Ltd  
Biohaven Pharmaceutical Holding Company Ltd  
BioLineRx Ltd  
Bionovis SA  
Biothera Pharmaceutical Inc  
Blueprint Medicines Corp  
Boehringer Ingelheim GmbH  
Boston Biomedical Inc  
BrightPath Biotherapeutics Co Ltd

Bristol-Myers Squibb Co  
Cadila Healthcare Ltd  
Calithera Biosciences Inc  
CanBas Co Ltd  
Cantargia AB  
Cascadian Therapeutics Inc  
CASI Pharmaceuticals Inc  
CBT Pharmaceuticals Inc  
Celgene Corp  
Cell Medica Ltd  
Celldex Therapeutics Inc  
Cellmid Ltd  
Cellular Biomedicine Group Inc  
Checkpoint Therapeutics Inc  
Chipscreen Biosciences Ltd  
Chugai Pharmaceutical Co Ltd  
Cielo Therapeutics Inc  
Cleave Biosciences Inc  
Cleveland BioLabs Inc  
Coherus BioSciences Inc  
Corcept Therapeutics Inc  
Cortice Biosciences Inc  
Corvus Pharmaceuticals Inc  
Critical Outcome Technologies Inc  
CSPC Pharmaceutical Group Limited  
CytomX Therapeutics Inc  
Cytori Therapeutics Inc  
DAE HWA Pharmaceutical Co Ltd  
Daiichi Sankyo Co Ltd  
DanDrit Biotech A/S  
Debiopharm International SA  
DEKK-TEC Inc  
DeIMar Pharmaceuticals Inc  
Denovo Biopharma LLC  
Domainex Ltd  
Double Bond Pharmaceutical International AB  
Dr. Reddy's Laboratories Ltd  
Dynavax Technologies Corp  
eFFECTOR Therapeutics Inc

Eisai Co Ltd  
Eleison Pharmaceuticals LLC  
Eli Lilly and Co  
EnGeneIC Ltd  
EntreChem SL  
Enumeral Biomedical Holdings Inc  
Enzene Biosciences Ltd  
EpiThany Inc  
Epizyme Inc  
Eudendron Srl  
Evotec AG  
Exelixis Inc  
F-star Biotechnology Ltd  
F. Hoffmann-La Roche Ltd  
FibroStatin SL  
Five Prime Therapeutics Inc  
Formosa Laboratories Inc  
Fountain Biopharma Inc  
Fujifilm Holdings Corporation  
G&E Herbal Biotechnology Co Ltd  
G1 Therapeutics Inc  
Galectin Therapeutics Inc  
Gene Techno Science Co Ltd  
Genelux Corp  
Genentech Inc  
Genmab A/S  
Genocea Biosciences Inc  
Genor BioPharma Co Ltd  
Genosco Inc  
Genzyme Corp  
Gilead Sciences Inc  
GlaxoSmithKline Plc  
Glenmark Pharmaceuticals Ltd  
GlycaNova Norway AS  
Glycotope GmbH  
Golden Biotechnology Corp  
Gradalis Inc  
Grunenthal GmbH  
Halozyme Therapeutics Inc

Hanmi Pharmaceuticals Co Ltd  
Heat Biologics Inc  
Helix BioPharma Corp  
Hemispherx Biopharma Inc  
Heptares Therapeutics Ltd  
HitGen LTD  
Horizon Pharma Plc  
Hutchison MediPharma Ltd  
iCeutica Inc  
Ideaya Biosciences Inc  
Ignyta Inc  
Immatix Biotechnologies GmbH  
Immune Design Corp  
Immune Pharmaceuticals Inc  
ImmunGene Inc  
Immunocore Ltd  
ImmunoGen Inc  
Immunomedics Inc  
Imugene Ltd  
Incyte Corp  
Infinity Pharmaceuticals Inc  
Inflection Biosciences Ltd  
Innovation Pharmaceuticals Inc  
Innovent Biologics Inc  
Inovio Pharmaceuticals Inc  
Invectys SA  
Inventiva  
IO Biotech ApS  
Io Therapeutics Inc  
Iovance Biotherapeutics Inc  
JHL Biotech Inc  
Jiangsu Hansoh Pharmaceutical Group Co Ltd  
Jiangsu Hengrui Medicine Co Ltd  
Jiangsu Kanion Pharmaceutical Co Ltd  
Johnson & Johnson  
Jounce Therapeutics Inc  
Juno Therapeutics Inc  
Kadmon Corp LLC  
Karyopharm Therapeutics Inc

Kite Pharma Inc  
Kura Oncology Inc  
Kyowa Hakko Kirin Co Ltd  
Laboratoires Pierre Fabre SA  
LATITUDE Pharmaceuticals Inc  
Leap Therapeutics Inc  
Les Laboratoires Servier SAS  
Lidds AB  
Loxo Oncology Inc  
Luye Pharma Group Ltd  
Lycera Corp  
MabVax Therapeutics Holdings Inc  
MacroGenics Inc  
Madrigal Pharmaceuticals Inc.  
Mallinckrodt Plc  
Mebiopharm Co Ltd  
MedImmune LLC  
Merck & Co Inc  
Merck KGaA  
Merrimack Pharmaceuticals Inc  
Mersana Therapeutics Inc  
Merus NV  
Microlin Bio Inc  
Millennium Pharmaceuticals Inc  
Mirati Therapeutics Inc  
Moderna Therapeutics Inc  
Molecular Partners AG  
MolMed SpA  
Morphotek Inc  
Multimmune GmbH  
Mundipharma International Ltd  
Mycenax Biotech Inc  
NanoCarrier Co Ltd  
NantKwest Inc  
Natco Pharma Ltd  
Nektar Therapeutics  
Neumedicines Inc  
NewLink Genetics Corp  
Northwest Biotherapeutics Inc

Novartis AG  
Oncobiologics Inc  
Oncolys BioPharma Inc  
Oncolytics Biotech Inc  
Ono Pharmaceutical Co Ltd  
Onxeo SA  
Optimum Therapeutics LLC  
OSE Immunotherapeutics  
Paranta Biosciences Ltd  
Peptomyc SL  
Peregrine Pharmaceuticals Inc  
Pfizer Inc  
Pharma Mar SA  
Philogen SpA  
Phosplatin Therapeutics LLC  
Pique Therapeutics  
Plexikon Inc  
Polaris Pharmaceuticals Inc  
Provectus Biopharmaceuticals Inc  
PsiOxus Therapeutics Ltd  
Puma Biotechnology Inc  
Purdue Pharma LP  
Qilu Pharmaceutical Co Ltd  
Qu Biologics Inc  
Qurient Co Ltd  
Rafael Pharmaceuticals Inc  
RaQualia Pharma Inc  
Reata Pharmaceuticals Inc  
Recombio SL  
Regeneron Pharmaceuticals Inc  
Rexahn Pharmaceuticals Inc  
Rgenix Inc  
Richter Gedeon Nyrt  
RS Research  
Samyang Holdings Corp  
Sanofi  
Scancell Holdings Plc  
SciClone Pharmaceuticals Inc  
ScinoPharm Taiwan Ltd

Seattle Genetics Inc  
Selvita SA  
Shanghai Fosun Pharmaceutical (Group) Co Ltd  
Shanghai Pharmaceutical Co Ltd  
Shionogi & Co Ltd  
Sierra Oncology Inc  
Sigma-Tau SpA  
SignPath Pharma Inc  
Simcere Pharmaceutical Group  
Sino Biopharmaceutical Ltd  
Sotio AS  
Spotlight Innovation Inc  
Starpharma Holdings Ltd  
Sumitomo Dainippon Pharma Co Ltd  
Sun Pharma Advanced Research Company Ltd  
SuviCa Inc  
Symphogen A/S  
Synactix Pharmaceuticals Inc  
Syndax Pharmaceuticals Inc  
Synermore Biologics Co Ltd  
Systemmune Inc



## I would like to order

Product name: Non-Small Cell Lung Cancer - Pipeline Review, H2 2017

Product link: <https://marketpublishers.com/r/NA28E2E58C0EN.html>

Price: US\$ 2,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/NA28E2E58C0EN.html>